Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

mized, controlled, open-label study is projected to enroll approximately 200 treatment-naive HIV-infected adult patients at more than 20 sites in North America, Central America, Europe and South Africa. Patients coinfected with hepatitis B or C may be included in the study.

The primary efficacy endpoint of the study is the mean change from baseline in viral load (log10 HIV RNA) at week 48 of treatment. A key secondary efficacy endpoint is the proportion of patients with plasma HIV RNA less than 50 copies/mL at week 48 of treatment.

The study will be conducted in two stages. In the first stage, 80 patients will be randomized (40 per treatment arm) into the study. When the 80 subjects from the first stage have completed 24 weeks of treatment, a formal interim analysis will be conducted and the results presented to an independent Data Safety Monitoring Board (DSMB) to assure the safety of the study participants. The study will be extended to stage 2 based on the results of the 24-week interim analysis; at which time an additional 120 patients (60 per treatment arm) will be enrolled. The final analysis will be conducted at week 48 of treatment for all patients.

Atazanavir boosted by ritonavir was selected for use in this study because it is recommended as an option for first-line therapy in both the International AIDS Society and Department of Health and Human Services guidelines for antiretroviral therapy. Additionally, it has been shown to have a more favorable lipid profile than other drugs in the PI class.

The study is being sponsored by Schering-Plough with support from Bristol-Myers Squibb.

About Vicriviroc Ongoing Phase III Studies in Treatment-Experienced Patients

Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc in adult treatment-experienced HIV-infected patients with R5-type virus only.

The two studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... the Friday, December 19 edition of USA ... (HIT) features Konica Minolta, the company announced today. The supplement will ... healthcare organizations. In addition to the print section ... New York , Chicago , ... Minneapolis and San Francisco , ...
(Date:12/19/2014)... TODAY, AEGATE, the leader in medicine verification ... of Peter Fox as Chief Technology Officer ... Officer. Peter has served as Development Director ... Oracle in 2011. Prior to Datanomic, Peter ... and subsequently Convergys, a world renowned billing system for ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... HARBIN, China , July 1 /PRNewswire-Asia-FirstCall/ ... manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese medicines, today ... the NYSE Amex. , , ... Renhuang expects to begin trading on ...
... BOSTON , July 1 China PharmaHub Corp. ("PharmaHub"), ... David Weaver and Dr. Michael Rynkiewicz .  In addition, ... of which it recently purchased a 77% interest.   , ... The management of World Wide Relics ("WWR") ...
Cached Medicine Technology:Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex 2Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex 3China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody 2China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody 3China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody 4
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, has ... company has recently updated its official blog with the ... Angeldress Blog has recommended some new designs ... itself in offering a huge selection of elegant products ... outfits are very carefully selected based on the design ...
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The aftermath of ... quite a stir, not only in Hollywood, but worldwide. ... 18th , the ripples of that attack are starting a ... jobs at risk. But they are not the only ... could be in for some embarrassing times ahead, agents and ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special offer (called ... Christmas. In the promotion, all buyers worldwide can enjoy ... something special for the women who are looking for ... new collections of 2015 dresses have been unveiled recently. ... discounted prices. Visit our website now before they are ...
Breaking Medicine News(10 mins):Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... 2011 The Nobel prize-winning physicist Richard Feynman once wrote ... people think?): "When I see equations, I see letters in ... what the hell it must look like to the students." ... Feynman,s experience of "seeing" the letters in colour was a ...
... colorectal cancer associated with taking aspirin or other nonsteroidal ... at risk because of elevations in a particular inflammatory ... the March issue of Gastroenterology , investigators from ... finding that higher baseline levels of a novel inflammatory ...
... Human social interactions are shaped by our ability to ... of the key features that enable us to identify individual ... age, and body size, that lead to a unique identity ... research has already determined the various brain regions responsible for ...
... million Americans may currently be misclassified as having abnormal ... Veterans Affairs Health Care System in Minneapolis and the ... that these people are not actually more likely to ... below 120/80. Taylor and colleagues, article in the ...
... of the brain called CADASIL, which strikes young ... misdiagnosed as multiple sclerosis, Loyola University Health System ... vessel walls blocks blood flow in the brain. ... strokes and mini strokes, depression, apathy, motor disability ...
... 8, 2011 Predictive Biomarker Sciences (PBS-Bio) has uncovered ... cancer cells. Previous studies have shown that over-activity ... cells to grow out of control. PBS-Bio, which is ... Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off ...
Cached Medicine News:Health News:Reading in 2 colours at the same time 2Health News:Aspirin's ability to protect against colorectal cancer may depend on inflammatory pathways 2Health News:How do we combine faces and voices? 2Health News:Redefining normal blood pressure 2Health News:Vascular brain disorder misdiagnosed as multiple sclerosis 2Health News:PBS-Bio uncovers how Unibioscreen drug kills cancer 2
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... unique microprocessor-controlled filter wheels for wavelength selection ... filter wheels can be programmed for excitation ... With this fluorometer, you do not have ... wavelengths. The C&L Dye Fluorometer can measure ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: